Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
<strong>ACR</strong> <strong>2023</strong><br />
Congress Preview<br />
Chair’s Introduction<br />
Dear Colleagues,<br />
Welcome to the <strong>Lupus</strong> Forum <strong>ACR</strong> <strong>2023</strong> Highlights <strong>Brochure</strong>, providing you with all you need to know about the lupus<br />
content at this year’s Convergence, including the Scientific Sessions, Posters, Abstracts, and Industry Symposiums.<br />
I’ve selected my Chair’s picks of the key content – I hope you find them useful.<br />
There’s plenty of great lupus content on Sunday, including the poster session, SLE – Treatment Poster I. In this session we<br />
see the reporting of post-hoc analyses of treatment responses by SF-36 in the anifrolumab Phase 3 long-term extension<br />
trial (0582), and the impact of belimumab on steroid use and disease activity from OBSErve (0587). Also within this session<br />
is a poster comparing IgA2 anti-dsDNA antibodies and clinical outcome in trials of belimumab after rituximab (0589),<br />
further data from the investigation into CAR T cell therapy in SLE (0607), and data on the efficacy of cenerimod in patients<br />
with high IFN-1 gene expression signature (0608). We then have three posters from <strong>Lupus</strong> Forum Steering Committee<br />
member, Richard Furie, on renal involvement in anifrolumab-treated SLE patients (0595), SRI-4 and BICLA responses from<br />
the Phase 2 trial of deucravacitinib (0596), and efficacy of anifrolumab assessed by improvements in SLEDAI-2K (0597).<br />
One final pick on Sunday comes in the Abstract Session, SLE – Treatment I: Renal, a post-hoc analysis of the Phase 2<br />
trial of lupus nephritis patients treated with obinutuzumab (0784).<br />
On Monday I would draw your attention to Pediatric Rheumatology – Clinical Poster II: Connective Tissue Disease,<br />
and a poster on belimumab safety in paediatric patients (1257) offering new data for this patient group. SLE – Treatment<br />
Poster II sees data on the year 5 follow up of belimumab safety (1499) and LLDAS achievement in patients receiving<br />
deucravacitinib (1501).<br />
Tuesday features my last three Chair’s picks. SLE – Treatment Poster III includes post-hoc analysis of belimumab efficacy<br />
by race and ethnicity (2347), while the abstract session, SLE – Treatment II: Nonrenal sees Phase 2 data on emerging<br />
treatments, ianalumab in SLE (2487), and CLASI achievement with deucravacitinib in patients with CLE (2489).<br />
We add new content to the <strong>Lupus</strong> Forum regularly, with monthly summaries of key publications, podcasts, and congress<br />
materials such as these. You can register for updates at lupus-forum.com or keep up to date by following us on Twitter<br />
@<strong>Lupus</strong>Forum and on LinkedIn by searching “<strong>Lupus</strong> Forum”.<br />
I hope you find our selection of highlights useful and that you enjoy the meeting in San Diego!<br />
Ed Vital<br />
Chair of the <strong>Lupus</strong> Forum Steering Committee; Associate Professor, University of Leeds<br />
Developed under<br />
the auspices of<br />
Supported with educational grants from<br />
Sponsorship<br />
received from
Key: CP Chair’s pick Abstract session Poster session<br />
Scientific session<br />
Key <strong>Lupus</strong> Content<br />
Sunday, 12 November <strong>2023</strong><br />
09:00–<br />
10:00<br />
09:00–<br />
10:00<br />
09:00–<br />
11:00<br />
0006<br />
09:00–<br />
11:00<br />
0014<br />
09:00–<br />
11:00<br />
0178<br />
09:00–<br />
11:00<br />
0543<br />
0560<br />
09:00–<br />
11:00<br />
0582<br />
<strong>Lupus</strong> Prevention and Disease-Modifying<br />
Anti-<strong>Lupus</strong> Drugs (DMALDs), Are We There Yet?<br />
Anca Askanase, Maria Dall’Era, David Karp<br />
Under Pressure: Updates in <strong>Lupus</strong> Nephritis<br />
Simone Appenzeller, Hermine Brunner,<br />
Mark Mitsnefes<br />
B Cell Biology & Targets in Autoimmune<br />
& Inflammatory Disease Poster<br />
Preclinical Characterization of a Novel anti-CD40<br />
Antagonist Antibody-glucocorticoid Conjugate<br />
with Superior Preclinical Efficacy and Favorable<br />
Safety Profile<br />
Wenming Ren<br />
Genetics, Genomics & Proteomics Poster<br />
The 330 Genetic Risk Loci of Systemic <strong>Lupus</strong><br />
Erythematosus (SLE) Now Known Are Consonant<br />
with Multiple Causal Mechanisms Involving<br />
Epstein-Barr Virus (EBV)-Encoded Transcription<br />
Co-factors (TFs) in EBV-Infected B Cells<br />
Viktoryia Laurynenka<br />
Healthcare Disparities in Rheumatology<br />
Poster 1: <strong>Lupus</strong><br />
Traditional and <strong>Lupus</strong>-Specific Risk Factors<br />
for Cardiovascular Events Among Patients with<br />
Systemic <strong>Lupus</strong> Erythematosus<br />
Saloni Patolia<br />
SLE – Diagnosis, Manifestations,<br />
& Outcomes Poster I<br />
Sensitivity of the 2019 European Alliance of<br />
Associations for Rheumatology/American College<br />
of Rheumatology Classification Criteria for<br />
Systemic <strong>Lupus</strong> Erythematosus in a Populationbased<br />
Cohort; A Study Set in Norway 2000–2015<br />
Hilde Haukeland<br />
Genetic Determinants of <strong>Lupus</strong> Nephritis and<br />
Kidney Function in Systemic <strong>Lupus</strong> Erythematosus<br />
Linda Hiraki<br />
SLE – Treatment Poster I<br />
Evaluation of Anifrolumab Treatment<br />
Responses by the Short Form 36 Health<br />
Survey Version 2 in SLE: A Post Hoc<br />
Analysis of the Placebo-Controlled Phase 3<br />
Long-Term Extension Trial<br />
Vibeke Strand<br />
CP<br />
0583<br />
0584<br />
0587<br />
0588<br />
0589<br />
0590<br />
0591<br />
0592<br />
0593<br />
0594<br />
0595<br />
Therapeutic Potential of Imvotamab, a<br />
CD20-Targeted Bispecific IgM T Cell Engager,<br />
for the Treatment of Refractory Autoimmune<br />
Disease Patients<br />
Racquel Domingo-Gonzalez<br />
Targeting Key Components of SLE Pathogenesis<br />
with the Multifaceted Immunomodulatory<br />
Properties of Cenerimod, a Selective S1P1<br />
Receptor Modulator<br />
Marianne Martinic<br />
Impact of up to 24 Months Intravenous (IV) CP<br />
Belimumab (BEL) Treatment on Steroid Use<br />
and Disease Activity in Patients with SLE in<br />
Clinical Practice: Additional Post Hoc Pooled<br />
Analysis of Multicountry OBSErve Cohort Data<br />
Roger A Levy<br />
Long Term Safety and Predictors of Serious<br />
Infections Among Patients with Systemic <strong>Lupus</strong><br />
Erythematosus Treated with Rituximab: Audit from<br />
a Single Center Biologic Registry<br />
Augustine Jose<br />
A Comparative Evaluation of IgA2<br />
Anti-dsDNA Antibodies and Clinical<br />
Outcome in Two Clinical Trials of Belimumab<br />
After Rituximab in SLE<br />
Muhammad RA Shipa<br />
Comparing Safety and Efficacy of Sodium-Glucose<br />
Co-Transporter 2 Inhibitors versus Dipeptidyl<br />
Peptidase 4 Inhibitors in Patients with Systemic<br />
<strong>Lupus</strong> Erythematosus and Comorbid Type 2<br />
Diabetes Mellitus<br />
Jui-En Lo<br />
Despite Dramatic Expansion of Approved Biologics<br />
in SLE, Unmet Needs Remain<br />
Ryan Rex<br />
Real-World Treatment Patterns in Patients with<br />
Systemic <strong>Lupus</strong> Erythematosus: An Analysis of<br />
the SLE Prospective Observational Cohort Study<br />
(SPOCS)<br />
Martin Aringer<br />
<strong>Lupus</strong> Nephritis of the Spanish National Registry<br />
of Belimumab in Patients with Systemic <strong>Lupus</strong><br />
Erythematosus<br />
Vicente Aldasoro<br />
Baseline Innate Immunity Transcriptional<br />
Signatures Act as Predictors of Response to<br />
Immunosuppressive and Biologic Treatments in<br />
Systemic <strong>Lupus</strong> Erythematosus While Disturbances<br />
Linked to p53-signaling Define “Resistant” Disease<br />
Panagiotis Garantziotis<br />
Renal Involvement in Patients with<br />
Systemic <strong>Lupus</strong> Erythematosus Treated<br />
with Anifrolumab Compared with Placebo<br />
over a 4-Year Period<br />
Richard A Furie<br />
CP<br />
CP
Key: CP Chair’s pick Abstract session Poster session<br />
Scientific session<br />
0596<br />
0597<br />
0598<br />
0599<br />
Deucravacitinib, an Oral, Selective,<br />
CP<br />
Allosteric Tyrosine Kinase 2 Inhibitor, in a<br />
Phase 2 Trial in Systemic <strong>Lupus</strong> Erythematosus<br />
(SLE): Achievement of Sustained SRI(4),<br />
BICLA and Dual Responses over 48 Weeks<br />
Richard A Furie<br />
Efficacy of Anifrolumab in Systemic<br />
CP<br />
<strong>Lupus</strong> Erythematosus by Overall and<br />
Organ-Specific SLEDAI-2K Improvements:<br />
Results from the Randomized, Placebo-<br />
Controlled Phase 3 Long-Term Extension Study<br />
Richard A Furie<br />
Litifilimab Modulates Type I IFN Biomarkers<br />
in Patients with SLE or CLE in the Phase 2<br />
LILAC Study<br />
Richard A Furie<br />
Targeted Inhibition of Cathepsins Limits the<br />
Intracellular Complement Activation in <strong>Lupus</strong><br />
Nephritis Podocytes<br />
Ana Kunzler<br />
0782<br />
0784<br />
16:00–<br />
17:30<br />
0847<br />
Comparison of Dual-immunosuppressive<br />
Therapy with a Voclosporin-based, Tripleimmunosuppressive<br />
Regimen for <strong>Lupus</strong> Nephritis<br />
in the ALMS and AURORA 1 Studies<br />
Maria Dall’Era<br />
Kidney-Related Outcomes and Steroid-<br />
Sparing Effects in Patients with Active<br />
<strong>Lupus</strong> Nephritis Treated with Obinutuzumab:<br />
A Post Hoc Analysis of a Phase 2 Trial<br />
Brad Rovin<br />
SLE – Diagnosis, Manifestations,<br />
& Outcomes I: Biomarkers<br />
Development of an IFN 5-Gene Signature Score<br />
to Identify IFN-high and IFN-low Subsets and as a<br />
Pharmacodynamic Biomarker for Deucravacitinib<br />
Treatment in a Phase 2 Trial in Patients with<br />
Systemic <strong>Lupus</strong> Erythematosus<br />
Chun Wu<br />
CP<br />
0600<br />
0604<br />
0606<br />
0607<br />
0608<br />
12:00–<br />
13:00<br />
14:00–<br />
15:30<br />
0781<br />
Identification of Subsets of SLE Patients<br />
Responsive to Baricitinib by Transcriptomic<br />
Analysis at Baseline<br />
Prathyusha Bachali<br />
Is Belimumab Dose Optimization Possible in<br />
Patients with Systemic <strong>Lupus</strong> Erythematosus?:<br />
Analysis of This Therapeutic Strategy in a Large<br />
Multicenter Cohort of Patients from Spanish<br />
Rheumatology Departments<br />
Irene Altabas Gonzalez<br />
Risk of Damage Progression with Belimumab<br />
versus Oral Immunosuppressant Use in Patients<br />
with Systemic <strong>Lupus</strong> Erythematosus<br />
April Jorge<br />
CAR T Cell Therapy Leads to Long-term<br />
Abrogation of Autoimmunity in SLE<br />
Patients While Vaccination Responses<br />
Are Maintained<br />
Georg Schett<br />
Efficacy of Cenerimod in Patients with<br />
High IFN-1 Gene Expression Signature and<br />
High Anti-dsDNA Antibody Levels: Post-hoc<br />
Analysis from a Phase 2 Study<br />
Anca Askanase<br />
Interventions to Increase Minority Participation in<br />
<strong>Lupus</strong> Clinical Trials<br />
Irene Blanco, Saira Sheikh<br />
SLE – Treatment I: Renal<br />
Low vs. High Initial Oral Glucocorticoid Dose for<br />
<strong>Lupus</strong> Nephritis Induction Treatment: A Pooled<br />
Analysis of Randomized Controlled Clinical Trials<br />
Amit Saxena<br />
CP<br />
CP<br />
Monday, 13 November <strong>2023</strong><br />
07:30–<br />
08:30<br />
09:00–<br />
11:00<br />
0928<br />
09:00–<br />
11:00<br />
1227<br />
1247<br />
09:00–<br />
11:00<br />
1489<br />
1490<br />
Meet the Panel: The Latest in <strong>Lupus</strong> Treatment<br />
Maria Dall’Era, Richard A Furie, Marta Mosca<br />
SLE – Etiology & Pathogenesis Poster<br />
Skewing of B Cell Receptor Repertoire in<br />
Unswitched Memory B Cells Is Associated with<br />
Disease Activity of Systemic <strong>Lupus</strong> Erythematosus<br />
and Targeted by Belimumab<br />
Keishi Fujio<br />
Pediatric Rheumatology – Clinical Poster II:<br />
Connective Tissue Disease<br />
Serious Infections Following Rituximab<br />
Administration in Children with Systemic<br />
<strong>Lupus</strong> Erythematosus<br />
Jordan Roberts<br />
Pharmacokinetic, Pharmacodynamic, and<br />
Safety Profile of Subcutaneous Belimumab<br />
in Pediatric Patients with Systemic <strong>Lupus</strong><br />
Erythematosus: Analysis of Data from a<br />
Multicenter, Open-Label Trial<br />
Hermine Brunner<br />
SLE – Treatment Poster II<br />
Treatment with Upadacitinib in Patients with<br />
Systemic <strong>Lupus</strong> Erythematosus Results in the<br />
Inhibition of B-Cell–related Biomarkers: Analysis<br />
of the M19-130 (SLEek) Phase 2 Study<br />
Marie-Claude Gaudreau<br />
Early Experience with SGLT2i in Systemic<br />
<strong>Lupus</strong> Erythematosus<br />
Michelle Petri<br />
CP
Key: CP Chair’s pick Abstract session Poster session<br />
Scientific session<br />
1492<br />
1493<br />
1494<br />
1495<br />
1496<br />
1498<br />
1499<br />
1500<br />
Pre-treatment Differentially Expressed<br />
Metagenes Characterize Systemic <strong>Lupus</strong><br />
Patients Who Subsequently Achieve Clinical<br />
Response to Belimumab<br />
Miles Smith<br />
Novel BCMA-CD19 Compound CAR-T (cCAR)<br />
Targets B Cells and Plasma Cells Achieving<br />
Immune Reset and Eliminates All Autoantibodies<br />
in Systemic <strong>Lupus</strong> Erythematosus (SLE) and <strong>Lupus</strong><br />
Nephritis (LN) Patients Resulting in Long-Term,<br />
Medication-Free Remission<br />
Greg Deener<br />
The Effect of Belimumab on Steroid Use in<br />
Patients with SLE: Results from a Retrospective<br />
Observational Study of Real-World Data from a<br />
US Rheumatology Provider Network<br />
Karen Worley<br />
Deep Serological Profiling of SLE Patients Treated<br />
with anti-CD19 CAR T Cells<br />
Samik Basu<br />
Clinical Safety and Efficacy Results from<br />
EQUALISE Type B: A Phase 1b Open-label Clinical<br />
Study of Itolizumab, a Novel anti-CD6 Therapy, in<br />
Subjects with Active Proliferative <strong>Lupus</strong> Nephritis<br />
Kenneth Kalunian<br />
First-in-Human Safety, Tolerability,<br />
Pharmacokinetics, and Pharmacodynamics<br />
Study of DS-7011a, an Anti-TLR7 Antagonistic<br />
Monoclonal Antibody for the Treatment of<br />
Systemic <strong>Lupus</strong> Erythematosus<br />
Giorgio Senaldi<br />
Year-5 Follow-up of Belimumab Safety CP<br />
(Mortality and Malignancies) in Patients with<br />
Systemic <strong>Lupus</strong> Erythematosus (SLE) Who<br />
Completed a Phase 4, 52-week, Randomized,<br />
Double-blind Placebo-controlled Safety Study<br />
Saira Sheikh<br />
Cumulative Infections by Week 52 Among<br />
Patients with SLE: A Summary of Data from<br />
Placebo-Controlled Belimumab Studies<br />
Saira Sheikh<br />
1504<br />
1505<br />
1507<br />
1508<br />
1511<br />
1512<br />
14:00–<br />
15:00<br />
16:00–<br />
17:30<br />
1694<br />
1696<br />
Characteristics and Prior Treatment Journey of<br />
Systemic <strong>Lupus</strong> Erythematosus (SLE) Patients<br />
Who Were Prescribed Anifrolumab – Observations<br />
from the American Rheumatology Network (ARN)<br />
in the U.S<br />
Vasileios Kyttaris<br />
Long-term Safety and Efficacy of Voclosporin in<br />
Black Patients with <strong>Lupus</strong> Nephritis: Results from<br />
the AURORA 1 and AURORA 2 Studies<br />
Gabriel Contreras<br />
Pharmacodynamic Changes in SLE Relevant Gene<br />
Expression Induced by Deucravacitinib in Patients<br />
Enrolled in the Phase 2 PAISLEY Trial<br />
Yanhua Hu<br />
Predicting in Virtual Patients the Efficacy of an<br />
Anti IFNa Mab in Cutaneous <strong>Lupus</strong> Erythematosus<br />
Philippe Moingeon<br />
B-Cell Recovery in a Randomized Controlled Trial<br />
of B-Cell Depletion with Obinutuzumab for the<br />
Treatment of Proliferative <strong>Lupus</strong> Nephritis<br />
Ed Vital<br />
Rituximab Objective Outcome Measures Trial in<br />
SLE (ROOTS): Randomised and Rescue Therapy<br />
Outcomes from a Randomised Controlled Trial<br />
Ed Vital<br />
Cutting Through the Brain Fog: Cognitive<br />
Dysfunction in <strong>Lupus</strong><br />
Ian Bruce, Carla Cuda, Meggan Mackay<br />
SLE – Diagnosis, Manifestations,<br />
& Outcomes II: Omics<br />
Transcriptomic Analysis of the Impact of<br />
Iberdomide on Patients with SLE<br />
Peter Lipsky<br />
Multi-Omic Profiling Reveals Immune Cell<br />
Priming Signature Linked to Systemic <strong>Lupus</strong><br />
Erythematosus Prognosis<br />
Sarfaraz Hasni<br />
1501<br />
<strong>Lupus</strong> Low Disease Activity State (LLDAS) CP<br />
Achievement with Deucravacitinib, an Oral,<br />
Selective, Allosteric Tyrosine Kinase 2 Inhibitor,<br />
in a Phase 2 Trial in SLE<br />
Eric Morand<br />
1502<br />
Introduction of Belimumab Within Five Years of<br />
the Onset of Systemic <strong>Lupus</strong> Erythematosus (SLE)<br />
Contributes to the Better Therapeutic Response;<br />
A Multi-center Retrospective Cohort Study<br />
Kanako Kojima<br />
1503<br />
Disease Course and Complement as Predictors<br />
of Response to Standard of Care Plus Placebo<br />
in Patients with SLE: A Post Hoc Analysis of<br />
Dapirolizumab Pegol and Epratuzumab Clinical<br />
Trial Data<br />
Joan Merrill
Key: CP Chair’s pick Abstract session Poster session<br />
Scientific session<br />
Tuesday, 14 November <strong>2023</strong><br />
09:00–<br />
10:00<br />
<strong>Lupus</strong> in Africa<br />
Ida Dey, Hakeem Olaosebikan, Kate Webb<br />
2333<br />
Dapirolizumab Pegol Impacts Important<br />
Immunologic Pathways in SLE: Pharmacodynamic<br />
Analysis of B Cell and Type I Interferon Pathways<br />
from a Phase 2b Trial<br />
Ioana Cutcutache<br />
09:00-<br />
11:00<br />
2024<br />
09:00–<br />
11:00<br />
2264<br />
2277<br />
Patient Outcomes, Preferences,<br />
& Attitudes Poster III<br />
Patient-Reported Outcomes in Patients with <strong>Lupus</strong><br />
Nephritis: A Post Hoc Analysis of Control Arm<br />
Data from Two Completed Phase III Randomized<br />
Clinical Trials<br />
Lisa Lindsay<br />
SLE – Diagnosis, Manifestations,<br />
& Outcomes Poster III<br />
Proposal for Defining Moderate and Severe<br />
Activity States in Systemic <strong>Lupus</strong> Erythematosus.<br />
Impact on Flares and Other Outcomes<br />
Ivonne Lourdes Mamani Velarde<br />
Patients with Systemic <strong>Lupus</strong> Erythematosus:<br />
A Comparative Study Between Two Large,<br />
Multi-centric, Spanish and Argentinian Registers,<br />
Focused on Outcomes Differences<br />
Iñigo Rúa-Figueroa<br />
2334<br />
2336<br />
2337<br />
2338<br />
Remission Attainment in Patients with Systemic<br />
<strong>Lupus</strong> Erythematosus Treated with Anifrolumab<br />
Compared with Placebo over a 4-Year Period<br />
Ronald van Vollenhoven<br />
Identification of Urine Metabolites Linked<br />
to Disease Activity That Are Modulated by<br />
Anifrolumab in a Phase 2 LN Trial Using<br />
Untargeted Metabolomics Analysis<br />
David Jayne<br />
Safety and Tolerability of NIM-1324, an Oral,<br />
Once-daily LANCL2 Agonist, in a Randomized,<br />
Double-Blind, Placebo-Controlled Phase 1 Study<br />
in Normal Healthy Volunteers<br />
Andrew Leber<br />
Results of Single-Arm, Phase 1b Study of<br />
Anti-C1q Treatment (ANX009) Show That the<br />
Classical Pathway Is a Key Driver of Complement<br />
Activation and Consumption in Patients with<br />
Active <strong>Lupus</strong> Nephritis<br />
Maria Dall’Era<br />
2296<br />
2297<br />
2306<br />
Association Between EQ-5D-5L and SLEDAI<br />
Scores in Patients with Systemic <strong>Lupus</strong><br />
Erythematosus in the United States and Europe:<br />
A Real-world Survey<br />
Ebuwa Igho-Osagie<br />
Interferon-α as a Biomarker to Predict Flares in<br />
<strong>Lupus</strong> Nephritis<br />
Laura Patricia Whittall Garcia<br />
Changes in Rheumatology Disease Measures<br />
After Initiation of Belimumab Treatment in Patients<br />
with Systemic <strong>Lupus</strong> Erythematosus<br />
Bernard Rubin<br />
2341<br />
2342<br />
2344<br />
Spanish National Registry of Belimumab in<br />
Patients with Systemic <strong>Lupus</strong> Erythematosus<br />
Vicente Aldasoro<br />
Modulation of B Cell and Interferon Pathways<br />
by Ianalumab in Patients with Systemic <strong>Lupus</strong><br />
Erythematosus: Findings from a Phase 2 Clinical Trial<br />
Thomas Dörner<br />
Telitacicept versus Belimumab for Patients<br />
with Active Systemic <strong>Lupus</strong> Erythematosus:<br />
A Retrospective, Multicenter, Real-world<br />
Observational Study<br />
Huizhi Jin<br />
09:00–<br />
11:00<br />
2326<br />
2328<br />
2331<br />
2332<br />
SLE – Treatment Poster III<br />
Efficacy and Safety of Voclosporin in Patients<br />
with Proteinuria > 2 G/g<br />
Emily Littlejohn<br />
Deucravacitinib, an Oral, Allosteric, Tyrosine<br />
Kinase 2 (TYK2) Inhibitor, in Patients with Active<br />
Systemic <strong>Lupus</strong> Erythematosus: Patient-Reported<br />
Outcomes in a Phase 2 Trial<br />
Marta Mosca<br />
Molecular Predictors of Treatment Response<br />
in Two Trials of Abatacept in Systemic <strong>Lupus</strong><br />
Erythematosus<br />
Kevin Thomas<br />
Dapirolizumab Pegol Efficacy by Subgroups in<br />
Patients with SLE: A Post Hoc Analysis of Phase<br />
2b Clinical Trial Data<br />
Anca Askanase<br />
2345<br />
2346<br />
2347<br />
2348<br />
Paired Kidney Biopsies from the AURORA 2 Study<br />
of Voclosporin in Active <strong>Lupus</strong> Nephritis<br />
Samir Parikh<br />
SLE Medication Usage and Organ Damage<br />
Among Adult SLE Patients with SLE Treated<br />
with Belimumab (BEL): Pooled Data from Three<br />
Open-Label Extension Studies over 11+ Years<br />
Zahi Touma<br />
Efficacy of Belimumab in Patients with<br />
Systemic <strong>Lupus</strong> Erythematosus by Race<br />
and Ethnicity: A Large Post Hoc Integrated<br />
Analysis of Five Clinical Trials<br />
Saira Sheikh<br />
Incidence of Infections Among Adult Patients<br />
with SLE Treated with Belimumab (BEL):<br />
Pooled Data from Three Open-Label Extension<br />
Studies over 11+ Years<br />
Jinoos Yazdany<br />
CP
Key: CP Chair’s pick Abstract session Poster session<br />
Scientific session<br />
2349<br />
2350<br />
2351<br />
11:00–<br />
12:00<br />
14:00–<br />
15:30<br />
2485<br />
2487<br />
2488<br />
2489<br />
2490<br />
Selection of the Dose for Subcutaneous<br />
Administration to Non-Japanese Subjects and<br />
Intravenous Administration to Japanese Subjects<br />
in the First-in-Human Study of DS-7011a, an<br />
Anti-TLR7 Monoclonal Antibody for the Treatment<br />
of Systemic <strong>Lupus</strong> Erythematosus<br />
Li Zhang<br />
Upregulation of Both APRIL and BAFF in Systemic<br />
<strong>Lupus</strong> Erythematosus Suggests Non-Redundant<br />
Roles, Further Revealed by Dual Inhibition with<br />
Povetacicept (ALPN-303; TACI vTD-Fc)<br />
Tiffany Blair<br />
Health Outcomes Among Patients (Pts) with SLE<br />
Initiating Belimumab (BEL) With and Without the<br />
Use of Immunosuppressants in the Previous 2 Years<br />
Karen Worley<br />
Advancing Non-Invasive Biomarkers in<br />
ANCA-Associated Vasculitis and <strong>Lupus</strong> Nephritis:<br />
A Translational State of the Art<br />
Salem Almaani, Andrea Fava, Brad Rovin<br />
SLE – Treatment II: Nonrenal<br />
Comparative Risk of Serious Psychiatric Events<br />
with Belimumab versus Oral Immunosuppressant<br />
Use in Patients with Systemic <strong>Lupus</strong> Erythematosus<br />
April Jorge<br />
Phase 2 Safety and Efficacy of Subcutaneous<br />
(s.c.) Dose Ianalumab (VAY736; Anti-BAFFR<br />
mAb) Administered Monthly over 28 Weeks in<br />
Patients with Systemic <strong>Lupus</strong> Erythematosus<br />
(SLE) of Moderate-to-Severe Activity<br />
Nan Shen<br />
Efficacy and Safety of ABBV-599 High Dose<br />
(Elsubrutinib 60 mg and Upadacitinib 30 mg)<br />
and Upadacitinib Monotherapy for the Treatment<br />
of Systemic <strong>Lupus</strong> Erythematosus: A Phase 2,<br />
Double-blind, Placebo-controlled Trial<br />
Joan Merrill<br />
Cutaneous <strong>Lupus</strong> Erythematosus Disease CP<br />
Area and Severity Index (CLASI) Achievement<br />
and Sustained Response with Deucravacitinib,<br />
an Oral, Selective, Allosteric Tyrosine Kinase 2<br />
Inhibitor, in a Phase 2 Trial in SLE<br />
Cristina Arriens<br />
Safety and Efficacy of Mycophenolate Mofetil<br />
in New-onset Systemic <strong>Lupus</strong> Erythematosus<br />
with High Titer of Anti-dsDNA Antibody and<br />
Without Major Organ Involvement: A Multicenter<br />
Randomized Controlled Trial<br />
Junna Ye<br />
CP<br />
14:00–<br />
15:00<br />
16:00–<br />
17:00<br />
16:00–<br />
17:30<br />
2551<br />
TeleRheumatology Research: Where We Are Today?<br />
Jeffrey Curtis, Leila Khalili, Daniel Solomon<br />
Personalized Nutrition for Patients with<br />
Rheumatic Diseases<br />
Danica Cowan, Hana Kahleova, Sarah Patterson<br />
SLE – Diagnosis, Manifestations,<br />
& Outcomes III: Disease Activity<br />
Remission and Low Disease Activity (LDA) in<br />
Patients with SLE Treated with Belimumab (BEL):<br />
Results from a Large Integrated Analysis<br />
Ioannis Parodis<br />
Wednesday, 15 November <strong>2023</strong><br />
08:00–<br />
09:00<br />
Heterogeneity in <strong>Lupus</strong>: Lessons from the<br />
Autoimmunity Centers of Excellence<br />
Marcus Clark, Virginia Pascual, Iñaki Sanz<br />
Industry Sessions<br />
Sunday, 12 November <strong>2023</strong><br />
18:00–<br />
20:00<br />
18:00–<br />
20:00<br />
Disease Modification: A Roadmap to Slowing<br />
Organ Damage Progression in Patients with SLE<br />
Angela Crowley, Ashira Blazer, Rajeev Ragahavn<br />
Novartis’ Commitment in Rheumatology<br />
Adam Winseck, Antton Egana, Kelly Montalto<br />
Monday, 13 November <strong>2023</strong><br />
18:00–<br />
20:00<br />
Expanding Horizons for SLE: An Innovative<br />
Therapy Option<br />
Michelle Petri, Richard Furie<br />
Tuesday, 14 November <strong>2023</strong><br />
11:30–<br />
12:15<br />
18:00–<br />
20:00<br />
A Rheumatologist and Nephrologist Discuss<br />
Kidney Preservation in <strong>Lupus</strong> Nephritis<br />
Sheetal Desai, Tina Kochar<br />
Exploring New Frontiers: CAR T Cell Therapy in<br />
Autoimmune Diseases<br />
James Chung, Peter Merkel, Georg Schett,<br />
Richard Furie, Brad Rovin, Amber Podoll, Peter Maag<br />
Developed under<br />
the auspices of<br />
Supported with educational grants from<br />
Sponsorship<br />
received from